Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul 14:2:690837.
doi: 10.3389/falgy.2021.690837. eCollection 2021.

Consensus Statements on the Approach to COVID-19 Vaccine Allergy Safety in Hong Kong

Affiliations

Consensus Statements on the Approach to COVID-19 Vaccine Allergy Safety in Hong Kong

Valerie Chiang et al. Front Allergy. .

Abstract

Background: Mass coronavirus disease 2019 (COVID-19) vaccination to achieve herd immunity is an effective means to mitigate the current COVID-19 pandemic. Reports of COVID-19 vaccine-associated allergic reactions and lack of clear local guidance are contributing factors leading to a low vaccine acceptance rate in the community. A task force of experts from the Hong Kong Institute of Allergy (HKIA) has been formed to address current needs. Objective: To formulate a set of consensus statements (CS) on COVID-19 vaccine allergy safety (VAS) in Hong Kong. Methods: A nominated task force of experts managing patients with drug and vaccine allergies in Hong Kong formulated the CS by the Delphi method. An agreement was a priori defined as ≥80% consensus. Results: A total of 11 statements met the criteria for consensus with good overall agreement among task force members, including seven statements on pre-vaccination recommendations and four statements on vaccination and post-vaccination guidance. Individuals with a history of suspected allergic reaction to prior COVID-19 vaccination should not receive further COVID-19 vaccination, and other groups at risk of COVID-19 vaccine-associated allergic reactions have been identified. The importance of pre-vaccination and post-vaccination assessment by frontline healthcare workers and evaluation by allergists are highlighted. Conclusion: The CS provides pragmatic and timely guidance for local frontline healthcare providers on decisions regarding COVID-19 VAS.

Keywords: COVID19; Hong Kong; allergy; consensus; safety; vaccine.

PubMed Disclaimer

Conflict of interest statement

AW is a consultant of ALK-Abelló A/S and director of Ksena Healthcare Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Graphical summary of consensus statements (CS).

References

    1. Who.int. Coronavirus Disease (COVID-19) Situation Reports. Who.int. (2021). Available online at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situatio... (accessed March 14, 2021).
    1. Scarbrough Lefebvre CD, Terlinden A, Standaert B. Dissecting the indirect effects caused by vaccines into the basic elements. Hum Vaccin Immunother. (2015) 11:2142–57. 10.1080/21645515.2015.1052196 - DOI - PMC - PubMed
    1. Wong MCS, Wong ELY, Huang J, Cheung AWL, Law K, Chong MKC, et al. . Acceptance of the COVID-19 vaccine based on the health belief model: a population-based survey in Hong Kong. Vaccine. (2021) 39:1148–56. 10.1016/j.vaccine.2020.12.083 - DOI - PMC - PubMed
    1. Australasian Society of Clinical Immunology and Allergy (ASCIA) . Allergy, Immunodeficiency, Autoimmunity and COVID-19 Vaccination Position Statement. Australasian Society of Clinical Immunology and Allergy (ASCIA). (2021). Available online at: https://www.allergy.org.au/hp/papers/ascia-hp-position-statement-covid-1... (accessed March 22, 2021).
    1. Vander Leek TK, Chan ES, Connors L, Derfalvi B, Ellis AK, Upton JEM, et al. . COVID-19 vaccine testing & administration guidance for allergists/immunologists from the Canadian Society of Allergy and Clinical Immunology (CSACI). Allergy Asthma Clin Immunol. (2021) 17:29. 10.1186/s13223-021-00529-2 - DOI - PMC - PubMed